GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Society of Clinical Oncology (ASCO)  (2)
  • 1
    Online Resource
    Online Resource
    A genetic risk score to personalize prostate cancer screening, applied to population data.
    American Society of Clinical Oncology (ASCO) ; 2019
    In:  Journal of Clinical Oncology Vol. 37, No. 7_suppl ( 2019-03-01), p. 181-181
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, No. 7_suppl ( 2019-03-01), p. 181-181
    Abstract: 181 Background: Genetic risk stratification may inform the decision of whether—and at what age—a man should undergo prostate cancer (PCa) screening. We previously validated a polygenic hazard score (PHS) for accurate prediction of age of onset of aggressive PCa and for improved screening PSA performance. The PHS is a weighted sum of 54 SNP genotypes. Here, we applied the PHS to population data to assess its potential impact on individualized screening. Methods: Age-specific PCa incidence data were obtained for men aged 40-70 years from the United Kingdom (Cancer Research UK, 2013-2015) and fit to an exponential curve as a continuous model of age-specific PCa incidence. Using hazard ratios estimated from ProtecT study data, annualized incidence rate curves were calculated for the following percentiles of genetic risk: 1, 5, 20, 50, 80, 95, and 99. The proportion of incidence classified as aggressive (Gleason score ≥7) was estimated as 59.7%, the reported result from the CAP trial. PHS was combined with incidence data to give a risk-equivalent age, when a man with given PHS percentile will have the same risk of aggressive PCa as that of a typical man at age 50 years. Results: The age-specific incidence rate of PCa for the UK population was modeled as: 0.004 e 0.203(age-40) ( R 2 = 0.957, p = 0.001). Table shows risk-equivalent age for each genetic risk percentile. For example, a man with a PHS in the 95th percentile reached PCa risk equivalent to a typical 50-year-old man at age 44 years; conversely, a man with a PHS in the first percentile does not reach this risk level until age 60 years. Initiation of screening discussions could be adjusted accordingly. Conclusions: PHS may inform PCa screening with individualized estimates of risk-equivalent age for aggressive PCa. Risk-equivalent age for aggressive prostate cancer, by PHS percentile. [Table: see text]
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2019.37.7_suppl.181
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2019
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Common genetic and clinical risk factors: Association with fatal prostate cancer in the Cohort of Swedish Men.
    American Society of Clinical Oncology (ASCO) ; 2021
    In:  Journal of Clinical Oncology Vol. 39, No. 6_suppl ( 2021-02-20), p. 65-65
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, No. 6_suppl ( 2021-02-20), p. 65-65
    Abstract: 65 Background: Clinical variables (age, family history, and genetics) are commonly used for prostate cancer risk stratification. Recently, polygenic hazard scores (PHS46, PHS166) were validated as associated with age at prostate cancer diagnosis. While polygenic scores, including PHS, are associated with all prostate cancer and are not specific for fatal cancers, PHS46 was also associated with age at prostate cancer death. We evaluated if adding PHS to available clinical variables improves associations with prostate cancer death. Methods: Genotype and phenotype data were obtained from a nested case-control subset (n=3,279; 2,163 were diagnosed with prostate cancer, 278 died of prostate cancer) of the longitudinal, population-based Cohort of Swedish Men. PHS and clinical variables (family history, alcohol intake, smoking, heart disease, hypertension, diabetes history, and body mass index) were independently tested via univariable Cox proportional hazards models for association with age at prostate cancer death. Multivariable Cox models were constructed with clinical variables and PHS. Log-likelihood tests compared models. Results: Median age at last follow-up and at prostate cancer death were 78.0 (IQR: 72.3-84.1) and 81.4 (75.4-86.3) years, respectively. On univariable analysis, PHS46 (HR 3.41 [95% CI 2.78-4.17]), family history (HR 1.72 [1.46-2.03] ), alcohol intake (HR 1.74 [1.40-2.15]), and diabetes (HR 0.53 [0.37-0.75] ) were each associated with prostate cancer death. A multivariable clinical model including PHS46 improved associations for fatal disease ( p 〈 10 −15 ). On multivariable analysis, PHS46 (HR 2.45 [1.99-2.97]), family history (HR 1.73 [1.48-2.03] ), alcohol intake (HR 1.45 [1.19-1.76]), and diabetes (HR 0.62 [0.42-0.90] ) all remained associated with prostate cancer death. Similar results were found using the newer PHS166. Conclusions: PHS had the most robust association with fatal prostate cancer in a multivariable model with common clinical risk factors, including family history. Adding PHS to clinical variables may improve individualized prostate cancer risk stratification strategies.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2021.39.6_suppl.65
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2021
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...